LifeMD price target lowered to $10 from $12 at B. Riley

B. Riley lowered the firm’s price target on LifeMD (LFMD) to $10 from $12 and keeps a Buy rating on the shares. LifeMD reported a Q3 top- and bottom-line miss with lowered guidance for the telehealth business, largely due to increased competition from compounded GLP-1 providers, the analyst tells investors in a research note. LifeMD is well-positioned entering 2026 with multiple drivers of growth, including oral semaglutide launch expected in January, Medicare obesity coverage, 503(a) pharmacy expansion, and ramping women’s health and behavioral health offerings.